Key statistics
As of last trade aTyr Pharma Inc (471A:DUS) traded at 2.90, -14.71% below its 52-week high of 3.40, set on Nov 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.78 |
---|---|
High | 2.90 |
Low | 2.78 |
Bid | 2.98 |
Offer | 3.08 |
Previous close | 2.74 |
Average volume | 565.56 |
---|---|
Shares outstanding | 83.94m |
Free float | 82.13m |
P/E (TTM) | -- |
Market cap | 250.15m USD |
EPS (TTM) | -0.9365 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:32 GMT.
More ▼
Announcements
- aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
- aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
- aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
- aTyr Pharma to Participate in September Investor Conferences
- aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
- aTyr Pharma Announces Research Study with Stanford Medicine
- aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
More ▼